Featured Press Releases

NS Pharma announces a leadership change, appointing new commercial head to drive strategic growth and innovation

NS Pharma announces a leadership change, appointing new commercial head to drive strategic growth and innovation

Dash Bio Secures $11M to Accelerate a New Era in Bioanalysis, Bringing Total Funding to $17.5M

Dash Bio Secures $11M to Accelerate a New Era in Bioanalysis, Bringing Total Funding to $17.5M

  • 23 Jul 2025

Dash Bio, a preclinical and clinical bioanalysis company reinventing the speed and scalability of...

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

To Revolutionize Coronary Artery Bypass Surgery, AMT Medical Secures $25 Million in Series B Funding

To Revolutionize Coronary Artery Bypass Surgery, AMT Medical Secures $25 Million in Series B Funding

Boehringer Ingelheim and the Lung Cancer Research Foundation Announce New Research Collaboration

Boehringer Ingelheim and the Lung Cancer Research Foundation Announce New Research Collaboration

Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards

Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

  • Tonix Pharmaceuticals Holding Corp.
  • 30 Jan 2026
China approves Libevitug, first-in-class therapy for hepatitis D

China approves Libevitug, first-in-class therapy for hepatitis D

  • Huahui Health Ltd.
  • 28 Jan 2026
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

  • Johnson & Johnson
  • 27 Jan 2026
Correction — Privo Technologies

Correction — Privo Technologies

  • Privo Technologies
  • 26 Jan 2026
HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

  • HanchorBio Inc.
  • 26 Jan 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.